Scientific Research and Innovation | Congen Pharma Awarded Boseine China Invention Patent
Publish Time:
2024-02-06

Recently, Congen Pharma's invention patent application, "A method for preparing high-purity Bakuchiol," was officially authorized by the State Intellectual Property Office, patent number: ZL202310496185.9.
This patented process successfully solves the technical challenges in Bakuchiol production, effectively removing salt, boron, and impurities, improving the purity of Bakuchiol, and bringing consumers a safer and more effective skincare experience.

01
Technical Background
Studies have shown that, Bakuchiol can promote the formation of intercellular mucopolysaccharides, thereby rebuilding cell structure, enhancing the connectivity between the dermis and epidermis, improving the binding ability of the dermis and epidermis, and thus achieving a beauty and anti-wrinkle effect.
However, the quality and purity of Bakuchiol directly affect the product's effectiveness. Traditional synthesis methods have various problems, the most prominent of which is the excessively high boron content in the product, while long-term use of boron-containing cosmetics may damage the skin.
02
Congen Pharma Patent Technology:
Achieving the production of high-purity Bakuchiol without salt or boron
Through extensive research and experiments, the Congen Pharma R&D team finally achieved a breakthrough, improving the purity of Bakuchiol from the source.
This invention method does not require electroosmosis or ion exchange columns or other desalting equipment, does not use relatively dangerous boron-free reducing agents, does not use heavy metal catalysts and special hydrogenation equipment, and achieves complete desalination and boron removal through extraction alone, realizing the production of boron-free and salt-free Bakuchiol.
Organic impurities were removed through crystallization of the triacyl Bakuchiol intermediate, which solved the problem that products with S:R=5:5 could not remove organic impurities through crystallization, and can provide high-purity salt-free and boron-free Bakuchiol products with 7-position S:R=5:5 to 100% S-type and conductivity below 10μs.
According to the test report, the Bisyne ® (Bakuchiol) produced using this patented process has a chemical purity >99%.

△Bisyne® ( Bakuchiol) chemical purity chromatogram
After rigorous testing by a third-party testing institution, Bisyne ® (Bakuchiol) content is as high as 99.5%, fully demonstrating its superior quality.

△Bisyne® ( Bakuchiol) content test report
Using SN/T3826-2014 Determination of boric acid and borate content in imported and exported cosmetics by inductively coupled plasma atomic emission spectrometry method, Bisyne ® (Bakuchiol), Bisyne ® 30 (9:1), Bisyne ® 30 (5:5) are all free of boric acid residue, with excellent quality and high batch stability.


△Bisyne ® ( Bakuchiol) no boric acid detected

△Bisyne ® 30 (9:1) no boric acid detected


△ Bisyne ® 30 (5:5) no boric acid detected
The acquisition of the Bakuchiol patent not only once again proves Congen Pharma's R&D strength but also sets a new benchmark for the industry. In the future, Congen Pharma will continue to adhere to scientific research as its core and innovation as its driving force, continuously breaking through technological barriers, bringing more innovative results to consumers and brand owners, and jointly promoting the sustained high-quality development of the industry.

Relevant Information

